Journal of Pharmaceutical Investigation

  • 제33권4호
  • /
  • Pages.287-292
  • /
  • 2003
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

암세포 표적지향화를 위한 항체-엔도스타틴 융합단백질의 체내동태 및 종양으로의 이행성

In Vivo Tumor Cell Distribution of Antibody-Endostatin Fusion Protein for Tumor-Specific Targeting and Pharmacokinetics

  • 강영숙 (숙명여자대학교 약학대학) ;
  • 이나영 (숙명여자대학교 약학대학)
  • 발행 : 2003.12.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A novel antitumor agent, antibody-endostatin fusion protein $(anti-HER2/neu\;IgG3C_H3-Endostatin,\;AEFP)$ formed by genetic engineering procedure from antibody (Ab) which specifically targets to tumor cells ad angiogenesis inhibitor, endostatin (Endo) that has excellent antitumor effect, minimizes the toxicity of normal cells and selectively kills only tumor cells. The purpose of this study is to evaluate the phamacokinetic parameters and to analyze the localization of AEFP. After an intravenous injection of $150\;{\mu}l\;(5\;{\mu}Ci)\;[^{125}I]Ab,\;[^{125}I]AEFP$ to mice, blood was collected though retroorbital plexus from 15 min to 2880 min. Following the jugular vein injetion of $150\;{\mu}l\;(10\;{\mu}Ci)\;[^{125}I]Endo$, blood was collected by the use of carotid artery cannulation from 0.25 min to 30 min. Consequently, Endo was very rapidly removed from plasma compartment within 30 min. On the other hand, AEFP similar to Ab was slowly cleared from plasma. Also, Endo was metabolized about 40% within 30 min. However, AEFP was shown to metabolize less than 10% within 2880 min. The organ distribution of Endo was in order kidney, lung, spleen. Both Ab and AEFP were localized in order spleen, kidney, liver. Futhermore the tumor/blood distribution ratio of AEFP at 96 hours after injection is about 20 times higher than it of Endo at one hour after injection. In conclusion, these studies demonstrate that the anti-cancer or suppression of angiogenesis effect of Endo may be improved by the use of AEFP because the longer half life and stability of AEFP is able to selectively target antigens expressed on tumors.

키워드

참고문헌

  1. J. Folkman. Angiogenesis and metastatic growth, Adv. Oncol., 12, 2-7 (1996)
  2. J. Folkman and D. Hanahan, Patterns and emerging mechanisms of the angiogenic switch during tumorgenesis, Cell, 86, 353-364 (1996) https://doi.org/10.1016/S0092-8674(00)80108-7
  3. T. Boehm, J. Folkman, T. Browder and M.S. O'Reilly. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390, 404-407 (1997) https://doi.org/10.1038/37126
  4. M.S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, E. Flynn, J.R. Birkhead, B.R. Olsen and J. Folkman. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277-285 (1997) https://doi.org/10.1016/S0092-8674(00)81848-6
  5. M. Dhanabal, R. Ramchandran, R. Volk, I.E. Stillman, M. Lombardo, M.L. Iruela-Arispe, M. Simons and V.P. Sukhatme. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma, Cancer Res., 59, 189-197 (1999)
  6. Y. Cao. Therapeutic potentials of angiostatin in the treatment of cancer, Haematologica, 84, 643-650 (1999)
  7. S.U. Shin, P. Friden, M. Moran, T. Olson, Y.S. Kang, W.M. Pardridge and S.L. Morrison. Transferrin-antibody fusion proteins are effective in brain targeting, Proc. Natl. Acad. Sci. USA, 92, 2820-2824 (1995) https://doi.org/10.1073/pnas.92.7.2820
  8. M.L. Penichet, J.S. Dela Cruz, S.U. Shin and S.L. Morrison. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors, Hum. Antibodies, 10, 43-49 (2001)
  9. J.S. Dela Cruz, K.R. Trinh, S.L. Morrison and M.L. Penichet. Recombinant anti-human HER2/neu IgG3-(GMCSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity, J. Immunol., 165, 5112-5121 (2000) https://doi.org/10.4049/jimmunol.165.9.5112
  10. Y.S. Kang. Vector-mediated delivery of ^{125}I-labeled opioid peptide, [Lys^{7}]dermorphin (K7DA), through the blood-brain barrier, J. Appl. Pharmacol., 5, 53-58 (1997)
  11. W.M., Pardridge, R.J. Boado and Y.S. Kang. Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier in vivo, Proc. Natl. Acad. Sci. USA, 92, 5592-5596 (1995) https://doi.org/10.1073/pnas.92.12.5592
  12. W.M. Pardridge, Y.S., Kang, A. Diagne and J.A. Zack. Cationized hyperimmune immunoglobulins: Pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice, J. Pharm. Exp. Ther., 276, 246-252 (1996)
  13. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, U.S.A., pp. 1-329 (1982)
  14. Y.S., Kang, R.J. Boado and W.M. Pardridge. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [^{32}P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate, Drug Metabol. Dispos., 23, 55-59 (1995)
  15. Y.S. Kang and W.M. Pardridge. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate, J. Pharm. Exp. Ther., 269, 344-350 (1994).
  16. Y.S. Kang. The determination of blood-brain barrier permeability and pharmacokinetics of a rat transferrin receptor monoclonal antibody by brain perfusion method and intravenous injection technique in mice, J. Appl. Pharmacol., 10, 37-42 (2002)
  17. S.U. Shin, D. Wu, R. Ramanathan, W.M. Pardridge and S.L. Morrison. Functional and pharmacokinetic properties of antibody-avidin fusion proteins, J. Immunol., 158, 4797-4804 (1997)
  18. M.L. Penichet, Y.S. Kang, W.M. Pardridge, S.L. Morrison and S.U. Shin. An antibody-avidin fusion protein specific for the transferrin receptor serve as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain, J. Immunol., 163, 4421-4426 (1999)
  19. J.Y. Lee, D.H. Kim, Y. Chung, S.U. Shin and C.Y Kang, Comparison of the antitumor efficacies of HER-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice, Vaccine, 21, 521-531 (2003) https://doi.org/10.1016/S0264-410X(02)00470-X
  20. K.M. Kim, E.Y. Shin, J.H. Moon, T.H. Heo, J.Y. Lee, Y. Chung, Y.J. Lee, H.M. Cho, S.U. Shin and C.Y. Kang, Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against HER-2/neu antigen, Int. J. Cancer, 102, 428-434 (2002) https://doi.org/10.1002/ijc.10732
  21. P.P Ng, J.S.D. Cruz, D.N. Sorour,J. M. Stinebaugh, S.U. Shin, D.S. Shin, S.L. Morrison and M.L. Penichet, An antitransferrin receptor-avidin fusion protein exhibits both strong proapototic activity and the ability to deliver various molecules into cancer cells, Proc.Natl.Acad. Sci. USA, 99, 10706-10711 (2002) https://doi.org/10.1073/pnas.162362999